WENDI KONOMOS: Open Payments
NPI 1699965533 · NEW BRAUNFELS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 32 payments from 11 companies in 2025. Trend: 2023 $635 · 2024 $495 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $181 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $173 |
| Vanda Pharmaceuticals Inc. | 2 | $57 |
| Melinta Therapeutics, LLC | 2 | $45 |
| Exact Sciences Corporation | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
| SANOFI-AVENTIS U.S. LLC | 1 | $24 |
| Gilead Sciences, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Novo Nordisk Inc | 1 | $16 |
Products named: JARDIANCE, VRAYLAR, FANAPT, QULIPTA, Rezzayo, CAPLYTA, DALVANCE, TZIELD.
Industry payments across TX — which companies pay providers there.
